Therapeutic Potential of Human Stem Cell Implantation in Alzheimer’s Disease

Hau Jun Chan †, Yanshree †, Jaydeep Roy ©, George Lim Tipoe, Man-Lung Fung and Lee Wei Lim *

School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China; lvnigel@connect.hku.hk (H.J.C.); yanshree@connect.hku.hk (Y.); jaydeep@connect.hku.hk (J.R.); tgeorge@hku.hk (G.L.T.); fungml@hku.hk (M.-L.F.)
* Correspondence: drlimleewei@gmail.com
† Joint-first authors.

Abstract: Alzheimer’s disease (AD) is a progressive debilitating neurodegenerative disease and the most common form of dementia in the older population. At present, there is no definitive effective treatment for AD. Therefore, researchers are now looking at stem cell therapy as a possible treatment for AD, but whether stem cells are safe and effective in humans is still not clear. In this narrative review, we discuss both preclinical studies and clinical trials on the therapeutic potential of human stem cells in AD. Preclinical studies have successfully differentiated stem cells into neurons in vitro, indicating the potential viability of stem cell therapy in neurodegenerative diseases. Preclinical studies have also shown that stem cell therapy is safe and effective in improving cognitive performance in animal models, as demonstrated in the Morris water maze test and novel object recognition test. Although few clinical trials have been completed and many trials are still in phase I and II, the initial results confirm the outcomes of the preclinical studies. However, limitations like rejection, tumorigenicity, and ethical issues are still barriers to the advancement of stem cell therapy. In conclusion, the use of stem cells in the treatment of AD shows promise in terms of effectiveness and safety.

Keywords: stem cells; neurogenesis; Alzheimer’s disease; stem cell therapy; neural stem cells; neurodegenerative disease; embryonic stem cells; mesenchymal stem cells; stem cell transplantation; Induced pluripotent stem cells

1. Introduction

Alzheimer’s Disease (AD) is a common neurodegenerative disease, accounting for 60–70% of neurocognitive disorder-related illnesses [1]. Neurocognitive disorder is an umbrella term covering a wide range of cognitive disorders that are increasingly common in the aging population, leading to considerable economic and societal burdens [2]. In 2015, 5.1 million individuals over the age of 65 were diagnosed with clinical AD in the United States, and over 47 million people worldwide were estimated to have neurocognitive disorders [3]. The number of cases is predicted to increase to 13.8 million in the United States and to more than 130 million worldwide by 2050 [4,5]. Key characteristic symptoms of AD include various cognitive impairments such as difficulty in remembering or recalling recent events [6]. The symptoms of AD can be categorized as mild, moderate, or severe. Individuals with mild AD symptoms are more likely to get lost, have poor judgment leading to bad decisions, increased anxiety, and personality changes. Individuals with moderate AD symptoms lose the ability to learn new things, have language problems such as reading and organizing thoughts, and have difficulty in recognizing family members. Individuals with severe AD symptoms experience weight loss, skin infections, difficulty in swallowing, and lose the ability to communicate [1].

One of the major risk factors for AD is age. A study by Guerreiro et al. identified a locus on chromosome 17 associated with onset age, with a specific variant CCL11 suspected
to be associated with the onset of AD \[7\]. Recent studies have established an association between depression and AD \[8\]. In 2021, Tanaka et al. demonstrated a link between AD and late-life depression by using resting-state functional magnetic resonance imaging. The dissociated functional connectivity pattern with decreased posterior default mode network (DMN) and increased anterior DMN is commonly observed in AD and late-life depression \[9\]. Aside from depression, gender is also a factor for AD risk, with a greater prevalence in females than males \[10–14\]. Some studies, such as Scheyer et al., have suggested a possible link between menopause and AD \[15–17\]. More recently, Sini et al. indicated several environmental factors could lead to AD. They found that cyanobacteria, present in natural water samples, can produce four classes of neurotoxins: saxitoxins, ciguatoxins, anatoxins, and $\beta$-N-methylamino-L-alanine (L-BMAA), which can all lead to an increased risk of AD \[18\]. Adding to the neurological disorders elicited by AD, some infections are more prone to appear in AD patients. Infections associated with AD include pneumonia, oral herpes, and spirochete bacterial infections causing Lyme disease and gum disease. These associated infectious illnesses can lead to chronic inflammation and eventually death \[19\]. Nonetheless, the life expectancy of AD patients following diagnosis can be up to 9 years \[6\].

The high rate of neuronal loss in AD patients can make treating this disorder difficult \[20\]. Conventional drug treatments that can restore brain tissue and improve cognitive functions can have undesirable side effects \[21\]. Stem cell therapy is a potential AD therapy that can overcome these undesirable outcomes. Stem cell therapy as a treatment for neurological disorders has been gaining interest in the field. With a self-renewal property, stem cells can go through numerous cycles of division and growth \[22\]. Stem cells can also differentiate into various specialized cell types \[23\]. These properties make stem cells a possible treatment option for AD by aiding in the proliferation and repair of damaged brain tissues \[21\]. Recent preclinical studies on stem cell therapy for AD have been promising and clinical trials on humans are ongoing. In this review, we first provide a brief description of AD etiology. Next, we summarize the current as well as the alternative treatments for AD. We further discuss the mechanisms of stem cells and their applications in preclinical studies and clinical trials. Lastly, we explore the limitations and possible future applications of stem cell therapy in AD.

2. Etiology of Alzheimer’s Disease

Alzheimer’s disease is a neurodegenerative disorder involving the accumulation of senile plaques and neurofibrillary tangles. Various neuropsychological, clinical, neuroimaging, and laboratory techniques are currently used to diagnose AD \[24\]. Individuals with AD exhibit key neuropathological changes including the deposition of extracellular beta-amyloid peptides as senile plaques \[25–28\] and accumulation of intracellular tau-containing neurofibrillary tangles in the brain \[29,30\]. All forms of AD have been found to involve senile plaques and almost all of them share increased production and decreased clearance of amyloid-beta peptides. However, certain mutations such as the “Arctic” mutation and “Osaka” mutation not only show slightly increased levels of amyloid-beta peptides, but also increased protofibrils and aggregations, respectively \[31,32\]. Amyloid-beta peptides are released by the cleavage of amyloid precursor protein (APP) \[6\] by two enzymes, beta-secretase and gamma-secretase \[33\]. Gamma-secretase is closely associated with presenilin (PSEN), and mutations in PSEN1 and PSEN2 can increase the synthesis of amyloid-beta \[34,35\]. However, the exact mechanism of how amyloid-beta proteins cause AD is not fully understood. Scientists have proposed that the aggregation and deposition amyloid-beta plaques in the brain activate neurodegeneration, leading to key symptoms such as memory loss \[36,37\]. Another prominent protein in the pathogenesis of AD is tau \[38\], which is a microtubule-associated protein that aids in the assembly and stabilization of microtubules. In AD, tau becomes hyperphosphorylated and assembles into paired helical filaments that detach from microtubules and attach to other tau molecules. They form threads that aggregate into neurofibrillary tangles, which block neuronal transport,
preventing the movement of molecules and nutrients from the cell body to dendrites and the axon, leading to disrupted synaptic communication [39].

Besides the main theories, there are several other hypotheses of the pathogenesis of AD. A current theory proposes a three-part mechanism involving decreased levels of blood lactic acid, folic acid, and increased levels of blood ceramide and adipokines [40]. These three mechanisms result in age-related characteristics, such as decreased muscle mass, change in diet, and increased visceral fat, respectively.

Lactic acid is synthesized in muscle cells and blood cells due to low oxygen levels. It is vital in supplying energy to brain cells like astrocytes and pericytes [41]. Inadequate levels of lactic acid can result in damage to the endothelial cells and pericytes in the blood–brain barrier, leading to brain damage. Studies have also shown that dietary changes in the aging population may contribute to inadequate folate intake [42–45]. As folate helps maintain the blood–brain barrier in protecting endothelial cells [46], a diet that contains adequate folate could aid in delaying the onset of AD and slow the cognitive decline in older adults [46,47]. High levels of ceramide have been discovered in the brain and blood of AD patients [48], which indicates that elevated levels of ceramide could lead to a greater risk of AD [49–52]. Ceramide induces oxidative stress and increases NADPH oxidase activity outside the plasma membrane of macrophages in the brain. This can increase hydrogen peroxide production, leading to damaged neurons in the brain [52]. Inflammatory adipokines can be secreted into the blood by visceral fat, causing arthritis, type 2 diabetes, heart disease, and neurological problems [50]. Visfatin, a type of adipokine, interacts with xanthine oxidase and NADH oxidase to boost the production of oxygen radicals in the capillary lumen. This can lead to oxidative damage in the blood–brain barrier, eventually damaging neurons [40]. In 2020, Tanaka et al. discovered increased levels of pro-inflammatory cytokines and neurotoxic kynurenines in neurodegenerative diseases including AD, which can damage the neuronal structure in the brain [53].

3. Current Treatments for Alzheimer’s Disease

Although some treatments for AD are available, their effectiveness is questionable due to the nature of AD [54]. Alzheimer’s disease is a multifactorial disease and is diagnosed through its clinical manifestation and underlying brain pathology. Typically, a disease should contain the following three basic factors: 1. An established biological cause, 2. A specific set of symptoms, and 3. Consistent anatomy changes. However, AD does not have an established cause and the symptoms are not well-defined. Moreover, the exact biological cause is not known, and the differential symptoms can vary from person to person, making it challenging to find a cure for AD. A study conducted by Salomone et al. noted challenges in treating AD due to the ineffectiveness of drug therapies [55]. Another review by Rijpma et al. also concluded that no single drug and nutrient-based therapy was clinically effective against AD [56]. Nevertheless, there are currently several drugs under clinical trial, and some have even been approved as treatments for AD. Possible interventions targeting metabolites and enzymes in the kynurenine pathway of tryptophan metabolism are also under investigation [57].

The currently approved drugs mainly alleviate symptoms and slow down the disease progression [57–61]. The N-methyl-D-aspartic acid (NMDA) receptor inhibitor and acetylcholinesterase inhibitor (AChEI) are two classes of approved medications for clinical use [62]. Acetylcholinesterase inhibitors (AChEIs) act by inhibiting synaptic clef cholinesterase from breaking down acetylcholine, thereby increasing cholinergic transmission in the cerebral cortex and basal forebrain [63,64]. Donepezil, rivastigmine, and galantamine are some examples of AChEI [65]. Another drug class effective against AD is NMDA receptor inhibitors. These drugs reduce the excitotoxicity generated by NMDA receptors excitation and protect the neuronal cells in the brain [66]. Memantines, a commonly used NMDA receptor antagonist, is also useful in relieving some symptoms [67]. Drugs with mechanisms of action relating to NMDA receptors are also under clinical trials [68,69]. AVP786 is a weak NMDA receptor antagonist and is currently under phase
3 trials; however, many trials have revealed it is ineffective for treating AD [70]. Another drug, B1425809, is a co-agonist of NMDA receptors and is currently being tested in phase 2 clinical trials [71]. Besides the above two drugs, gavestinel and AXS-05 are also undergoing clinical trials [72,73]. In recent years, novel drug targets have also been established. Drugs such as Solanezumab, Aducanumab, and Crenezumab are monoclonal antibodies targeting Aβ peptide [74]. These antibodies can bind to Aβ peptides and help to clear excess amyloid plaque and reduce sunaptotoxicity, eventually leading to improved cognition in AD patients [75–77]. Other drugs like Anavex 2–73 and GV-971 work by blocking tau hyperphosphorylation to reduce AD pathology [78].

Another way to develop drugs against AD is to repurpose existing drugs for dementia. Moreover, other drugs can be repurposed, including diabetes agents and vitamins, as well as drugs for a wide range of diseases from cardiovascular to psychiatric disorders [79]. For example, there is evidence that antioxidants (e.g., vitamin E at a dose of 2000 IU/day) can delay functional impairments [67,80]. Masitinib, a tyrosine kinase inhibitor which was originally used as a treatment for mast cell tumors, is also suggested to have anti-dementia effects [81]. Zolpidem, a sedative–hypnotic medicine prescribed for insomnia, is also a promising drug for treating AD [57,82]. Besides drug treatments, exercise programs have been shown to help AD patients physically, but they do not improve cognitive functioning [83].

Scientists are also looking at novel targets and approaches against AD. Current research includes genetic instability, post-translational modification, and lipid metabolism related to long interspersed nuclear element-1, micro RNAs, and apolipoprotein E4, respectively [84–91]. Calmodulin-binding proteins associated with calcium homeostasis [92] have also been shown to have therapeutic potential against AD. Additionally, kynurenine analogues, which are NMDA receptor antagonists and antioxidants, can reduce neurotoxicity in AD patients [53,93–98]. In 2021, Ibos et al. suggested the presence of a sex-dependent hemodynamic compensatory mechanism could also be a potential therapeutic direction in AD [99]. Diet-wise, the use of nutraceutical compounds can also possibly play a prophylactic role in AD. Supplemental use of nutraceutical inositol was suggested to prevent the onset and progression of the cognitive impairment in AD [100].

4. Alternative Strategies for the Treatment of Alzheimer’s Disease

Currently, there is no effective treatment that can cure AD. Recent clinical studies suggest that electrical stimulation might improve memory functions when specific brain regions are stimulated. Of particular interest is a single-case report in which electrical stimulation was used to treat a patient with morbid obesity, in which the electrical brain stimulation unexpectedly evoked autobiographical memory episodes in the patient [101]. In animal studies, experimental data showed that memory functions could be enhanced by stimulating the medial prefrontal cortex [102–105], entorhinal cortex, and perifornical region [106–108]. It has also been shown to induce antidepressant-like effects in animal studies [109,110]. Nevertheless, without in-depth mechanisms of preclinical studies, it is still a very premature phase to draw any conclusion on whether electrical stimulation will be suitable as a treatment for patients with dementia.

Drug therapies for AD, mainly given on an individual basis, can only temporarily improve some symptoms, but cannot stop or slow down the neurodegenerative process [111]. The low efficacy of these drugs is exemplified in the high risk/benefit ratio of AChEIs, where symptoms are only slightly improved when compared with a placebo [112]. Due to the low efficacy of current treatments, pharmaceutical companies and medical institutes have been actively seeking alternative therapies for AD, including stem cells transplantation.

5. Outline of the Review

The online PubMed database was searched for relevant articles between the years 2000 to 2021 in English using a Boolean operation with keywords “Alzheimer’s” AND
stem cell”. Relevant articles cited in the reference lists of the identified review articles were also included. The search found 153 preclinical studies with the majority of them published in 2020, and 708 clinical studies, of which 114 were also published in 2020. We used PubMed as it contains an extensive collection of indexed peer-reviewed journals. Another online database, ClinicalTrials.gov (accessed on 10 August 2010), was searched for relevant clinical trials using keywords “Alzheimer’s disease” and “stem cells”. We review selected preclinical studies and clinical trials of stem cell therapies for AD and discuss their efficacy and safety in AD patients. The mechanisms, therapeutic potential, and limitations of the stem cell therapies are also fully discussed.

6. Therapeutic Potential of Stem Cells

Rosenberg (1988) was the first to successful graft genetically modified cells in a damaged brain to protect cholinergic cells from dying [113]. However, this approach has drawbacks because it can only generate a small amount of tissue [114]. This pioneering study paved the way for stem cell implantation as a therapy for neurocognitive disorders. Another study in 1991 showed the engraftment of neuronal cells in specific brain regions was able to provide temporary relief in Parkinson’s disease by increasing the concentration of neurotransmitters, but it was unable to treat the disease [115].

A preclinical study by Wang et al. in 2006 investigated the effects of NSC transplantation in the cortex of an AD mouse model [116]. They transplanted mouse embryonic stem cell-derived neurospheres into the barrel field of the S1 cortex and frontal association cortex of C57BL/6 mice that had lesions of the nucleus basalis of Meynert (NBM) induced by ibotenic acid. Another group of mice receiving only embryonic stem cells served as the control. After 12 weeks of transplantation, mice were subjected to behavioral testing, which demonstrated the transplanted neurospheres in the cortex had survived and were able to produce more ChAT and serotonin-positive neurons within and near the implanted grafts. They found the mice with implanted neurospheres had significantly decreased working memory errors in the eight-direction maze test. On the contrary, treatment with embryonic stem cells in the control group led to teratomas, and no neurons were expressed, resulting in rapidly deteriorating working memory. In another study, neurospheres cultured from free floating clusters of NSCs were found to produce a positive effect in ameliorating the symptoms of AD in mice [117]. The form taken by the neural stem cells was found to greatly impact their effectiveness, as implanted embryonic stem cells not only had diminished positive effects, but also formed adverse teratomas. Various other similar investigations on animals were subsequently conducted to understand the effect of implanted stem cells in treating AD.

Later, scientists developed another form of stem cell therapy that involved pharmacological activation of endogenous neural stem cells and progenitors [118]. One example is epidermal growth factor (EGF) that is reported to be a critical mitogen for regulating neural stem cell growth and maintenance [119]. In stroke animals, intraventricularly administered EGF was able to increase neuronal differentiation rate in the striatum [120]. Teramoto et al. injected EGF and albumin intravenously in a mouse model of cerebral ischemia, which resulted in increased neuronal replacement by 100-fold [120]. They also found that newly developed immature neurons had migrated to the lesion site and differentiated into mature neurons, replacing more than 20% of the lost interneurons within 13 weeks. Although this method of stem cell therapy has not been widely applied in AD trials, the above experiment shows it has immense potential for treating AD.

7. Preclinical Research on Stem Cell Therapies in AD

Stem cell transplantation is a relatively new form of treatment in AD. To date, many studies have been conducted on stem cell therapies as a treatment for AD, but they have mostly been preclinical research. We selected several important preclinical studies to evaluate the effectiveness of stem cells therapies in AD rodent models (Table 1).
For in vitro experiments, stem cells or normal cells are usually cultured to test the direct effect of certain medications on cells and tissues [121]. For example, neurospheres can be formed from stem cells and are used to study extrinsic stimuli present in the neuronal microenvironment [122,123]. For stem cell therapy, stem cells need to be directly transplanted in vivo to elicit the effects. Thus, in vitro experiments are very important to ensure the safety and primary effectiveness of stem cell therapies. Early studies of stem cell therapy for AD by Farshed et al. investigated the generation of neurons using mouse embryonic stem cells (ESCs) [124]. After deriving ESCs from the C57BL/6 mice, stem cells were grown on a feeder layer of primary mouse embryonic fibroblasts in a tissue culture flask containing the Dulbecco’s modified eagle medium. Ref. [125] The neuronal precursor cells (NPCs) were then successfully differentiated for transplantation. Liu et al. in 2013 also performed a similar experiment using human ESCs [126]. They maintained the stem cells similar to Baharvand et al. and differentiated them into neuroepithelial cells and eventually into cholinergic spinal motor neurons [127]. To improve the differentiation and incubation procedure, Cheng et al. suggested the incorporation of electrical stimulation to promote stem cell neural differentiation [128].

After several in vitro studies successfully differentiated stem cells into a neural lineage, research then focused on mice with simulated AD pathology. Most of the mice in these studies were injected with Aβ1—42 to elicit AD-related symptoms. Before investigating the effectiveness of stem cells on rodent models, the safety of stem cell therapy needs to be investigated [128]. In 2011, Ra et al., conducted both preclinical and clinical studies on the safety of stem cell therapy. The preclinical study adopted comprehensively designed experiments to investigate the safety of intravenous infusion of human adipose tissue-derived MSCs (hAdMSCs) in immunodeficient mice [110]. The results showed the highest cell dose of $2.5 \times 10^8$ cells/kg body weight did not produce any adverse effects, and the SCID mice were healthy. A tumorigenicity test was performed in Balb/c-nu mice for 26 weeks, which showed the highest cell dose of $2 \times 10^8$ cells/kg body weight did not cause any tumor development, which confirmed the safety of MSC-derived neural stem cells in these rodent models [110]. A study by Farshad et al. successfully grew and differentiated stem cells in their laboratory. The implanted stem cells did not lead to tumor formation in lesioned rats, indicating these stem cells were safe for transplantation [124]. Besides their safety, the effectiveness of stem cell therapy in lesioned rats has also been demonstrated. Liu et al. observed that stem cell transplantation in injured rats reduced latency to find a hidden platform in the Morris water maze (MWM) test. The transplanted rats also showed a shorter latency to avoid an aversion stimulus in the passive avoidance test. The accuracy of the above tests was confirmed in the open field test, which also showed little variation in the anxiety level that would otherwise have obscured the results [126]. A more recent study conducted in 2021 by Gholamigeravand et al. injected selenium nanoparticles together with adipose-derived MSCs in an AD mouse model. Compared with stem cell injection alone, they showed the combination therapy could effectively enhance cognitive function, as demonstrated in the novel object recognition (NOR) test. They also observed that amyloid-β deposition was also greatly reduced. They found the migration and survival of transplanted stem cells was enhanced in the presence of selenium nanoparticles. These studies demonstrate that stem cell-based therapies are effective and show promise as potential treatments for AD [129].

Although the etiology of AD is known to be multifactorial, genetic factors have been shown to play an important role in the disease’s development [130]. With advances in genetics, rats can now be genetically altered to mimic the AD pathology in humans. Genetically modified rats that can recapitulate AD pathology have been used to study AD pathogenesis and to test the effectiveness of treatments. A preclinical study by McGinley et al. in 2018 transplanted human neural stem cells in the fimbria fornix of an AD B6C3-Tg mouse model. They found significant cognitive improvements in NOR and MWM tests. Although the levels of cholinergic neurons and synapse-related proteins were unaffected, the levels of amyloid plaque were greatly reduced. However, this study did not provide
sufficient details to validate the use of stem cell therapy in this preclinical model [131]. Another similar study by Kim et al. (2020) used human amniotic epithelial stem cells for implantation instead of human neural stem cells. They showed the stem cell transplantation was able to improve cognitive function in MWM and Y-maze tests. Furthermore, Congo red staining showed there were reduced levels of amyloid plaques in the mice brains. In addition, there was reduced activity of beta-secretase, which is involved in amyloid production [132,133]. A study by Losurdo et al. in 2020 administered MSC extracellular vesicles intranasally, which is a novel route of administration. They found the MSC-EVs could dampen the activation of microglia cells and increase dendritic spine density, suggesting neuroprotective effects in transgenic mice [134]. All these recent studies support the effectiveness of stem cell therapy on AD rodent models.
| Authors               | Models and Transgene                              | Dosage and Injection Site                                                                 | Type of Stem Cells | Behavioral Outcome                                                                 | Mechanisms & Physiological Effects                                                                                                                                 |
|----------------------|--------------------------------------------------|------------------------------------------------------------------------------------------|-------------------|-----------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1-6 Farshad et al., 2009 [124] | Sprague–Dawley rats with nucleus basalis of Meynert lesion | One surgery injection into coordinates from bregma: AP = −0.9, L = 2.8, V = 6.8 with 2 × 10⁵ cells in 2 μL. | Embryonic stem cells | Learning, memory, and spatial cognition improved in the MWM test | Successful in vitro differentiation of ESC to neuronal precursor cells. hESCs differentiated into primitive neuroepithelia, MGE-like progenitors, then into cholinergic spinal motor neurons in vitro. MGE progenitors efficiently induced by SHH, and ISL1, OLG2, and ASCL1 (expressed in lateral ganglionic eminence (LGE) and MGE cells in vivo). Grafted neural progenitor cells produced neurons and glia. |
| Liu et al., 2013 [126] | p75-saporin lesion models (8 to 10 weeks old)     | One surgery injection into ventricle with about 100,000 cells                           | hESCs (line H9, passages 18–35; line H1 passages 30–36) | Learning, memory, and spatial cognition improved in the MWM test | hESCs differentiated into primitive neuroepithelia, MGE-like progenitors, then into cholinergic spinal motor neurons in vitro. MGE progenitors efficiently induced by SHH, and ISL1, OLG2, and ASCL1 (expressed in lateral ganglionic eminence (LGE) and MGE cells in vivo). Grafted neural progenitor cells produced neurons and glia. |
| Ra et al., 2011 [135] | SCID mice (91 males and 91 females, 6 weeks old)  | One injection of different MSC dosages in the tail vein: Saline control Low dose (5 × 10⁶ hAdMSCs/kg B.W.) Medium dose (3.5 × 10⁷ hAdMSCs/kg B.W.) High dose (2.5 × 10⁸ hAdMSCs/kg B.W.) | MSCs              | No abnormal side effects                                                          | No specific pathological changes were observed in mice organs including lungs. No significant changes in the hematology, urine, ophthalmic test, and blood chemistry results. |
| Se et al., 2015 [136] | Male C57BL/6 mice receiving Aβ1–42 injection (6 weeks old, not transgenic) | One intracerebroventricular injection of 1.0 × 10⁶ cells/mouse                           | MSCs              | Behavioral analysis of the radial Arm Maze test showed the MSC treatment significantly improved cognitive memory performance | Short-term treatment with MSCs in Aβ-treated NPCs slightly increased expression of proliferation marker Ki-67 and neuronal progenitor markers GFAP, SOX2, and nestin without changing HuD expression. Long-term treatment significantly increased expression of the proliferation marker, neuronal progenitor markers, and the neuronal marker HuD compared to Aβ treatment alone. In Aβ-treated NPCs co-cultured with MSCs, long-term MSC treatment significantly increased expression of β-catenin and Ngn1 compared to Aβ treatment alone, showing Wnt/β-catenin signaling is involved in MSC-induced increased survival and neuronal differentiation in NPCs. MSCs enhanced expression of β-catenin and Ngn1 in AD animal models. Double-stained BrdU and Ngn1 cells in the hippocampus were frequently observed in MSC-treated AD animals. |
| Li et al., 2007 [137] | Sprague–Dawley rats with synthetic Aβ 1–40 amyloid protein injected | One injection with 2–3 × 10⁵ cells into the hippocampus                                  | BMSCs             | Cognition improved in the MWM                                                     | Transplanted cells expressing NGF survived and differentiated into ChAT-like neurons. |
### Table 1. Cont.

| Authors                          | Models and Transgene                                                                 | Dosage and Injection Site                                                                 | Type of Stem Cells | Behavioral Outcome                  | Mechanisms & Physiological Effects                                                                 |
|---------------------------------|--------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|-------------------|------------------------------------|---------------------------------------------------------------------------------------------------|
| 1-6 Gholamigervand et al., 2021 [129] | Adult male Wistar rats with streptozotocin-induced memory impairment                  | Five groups:                                                                             |                   |                                    | Synergistic effects of SeNPs and AMSCs on memory function in STZ-injected rats with decreased Aβ deposition. Administration of SeNPs enhanced migration, survival, and BDNF hippocampus concentration of transplanted AMSCs rats. |
|                                 |                                                                                      | 1. Intact control group.                                                                  |                   |                                    |                                                                                                   |
|                                 |                                                                                      | 2. Streptozotocin-injected group (STZ) received intracerebroventricular (ICV, 3 mg/kg) injection of streptozotocin in two half-doses on days 1 and 3. STZ group received single ICV transplantation dose of AMSCs (STZ + AMSC) 1 month after induction of the model. |
|                                 |                                                                                      | 3. STZ group received single ICV transplantation dose of AMSCs (STZ + AMSC) 1 month after induction of the model. |
|                                 |                                                                                      | 4. STZ-treated rats received daily oral administration of Se-NPs 0.4 mg/kg for 1 month (STZ + SeNP) via oral gavage feeding tube. |
|                                 |                                                                                      | 5. STZ-injected rats received both AMSCs and SeNPs (STZ + AMSC + SeNP).                   |                   |                                    |                                                                                                   |
| Losurdo et al., 2020 [134]      | Triple-transgenic 3xTg mice                                                          | PBS solution or extracellular vesicles in ~5 µL spurts per nostril                         | MSCs              | Not available                       | MSC-EVs decreased microglia activation in 3xTg AD mice. MSC-EVs increased dendritic spine density in 3xTg mice. |
| Kim et al., 2020 [133]          | Tg2576 mice expressing mutant human APP containing the Swedish (K670N/M671L) mutation  | Not given                                                                                | hAECS             | Spatial learning and memory were improved in MWM test | Transplantation of hAECS reduced amyloid burden.                                                                 |
| Chen et al., 2021 [136]         | J20 transgenic mouse model of C57BL/6 type (JAX-006293) and age-matched control group | One intravenous injection of 50 µg of purified MSC-exosomes (number not specified)        | MSCsh             | Cognitive function improved in the NOR test | MSC-exosomes decreased Aβ levels. MSC-exosomes prevented the downregulation of neuronal memory/synaptic plasticity-related genes such as Bdnf IV, SYP, GluR2, and GRIN2B. MSC-exosomes improved brain glucose metabolism as shown in the [18F] FDG-PET. MSC-exosomes inhibited astrocyte activation, upregulated neuronal memory, and synapse-related genes; levels of bdnfiv, syp, and glur1 were increased. HDAC4 expression decreased after treatment, and expressions of HDAC4 target genes Homer1 (Homer protein homolog 1), Syn2 (Synapsin II), and Lgi1 (leucine-rich glioma inactivated 1) were elevated. |
| Authors | Models and Transgene | Dosage and Injection Site | Type of Stem Cells | Behavioral Outcome | Mechanisms & Physiological Effects |
|---------|----------------------|--------------------------|-------------------|-------------------|----------------------------------|
| 1-6 Masako et al., 2020 [139] | Protein/presenilin 1 (APP/PS1) mice | Two times at a 2-week interval with $1 \times 10^5$ BM-MSCs per mouse via intracerebroventricular injection | BM-MSCs | Improved learning and memory impairment shown by the probe test and hidden platform MWM | BM-MSCs decreased glial fibrillary acidic protein (GFAP)- and tumor necrosis factor (TNF) α-positive areas in astrocytes. BM-MSCs decreased M1 type activated microglia and increased M2 type activated microglia in AD model mice. MSC-CM secreted C-X-C Motif Chemokine Ligand 5 (CXCL5), monocyte chemotactic protein-1 (MCP-1), beta-nerve growth factor (β-NGF), tissue inhibitor of metalloproteinase-1 (TIMP-1), and vascular endothelial growth factor-A (VEGF-A). The numbers of F4/80-positive macrophages and the intensity of transthyretin (TTR) were increased in CP. The expression of miR-146a in the hippocampus was significantly upregulated. Expression of TRAF6 in the subiculum area was significantly decreased. BM-MSC-derived exosomes suppressed the expression of NF-κB by transferring miR-146a into astrocytes. BM-MSC-derived exosomal miR-146a were taken up into astrocytes leading to anti-inflammatory effects. |
| Lu et al., 2021 [140] | APP/PS1 double transgenic mice expressing mutant human amyloid precursor protein (APPSwe) and presenilin 1 (PS1-dE9) under a mouse prion protein promoter | One injection with 8 µL ($1 \times 10^6, 4$ µL/side) of hNSCs or saline on both sides of the nasal cavity | hNSCs | Cognition was improved in NOR and MWM tests | hNSCs attenuated Aβ40 and Aβ42 accumulation in APP/PS1 mice and promoted clearance via increased IDE and NEP levels. hNSC transplantation reduced the density of astrocytes and microglia, indicating an inhibition of neuroinflammation. Intranasal transplantation of hNSCs enhanced endogenous neurogenesis, ameliorated pericytes, and synaptic loss in the hippocampus of APP/PS1 mice. Increased number of pericytes increased Aβ clearance by phagocytosis and transportation of Aβ out of the CNS through the BBB, maintaining BBB permeability, and supplying oxygen and metabolites in endothelial cells. Increased number of pericytes modulated neurogenesis and angiogenesis correlated with cognition. |
| Li et al., 2016 [141] | APP/PS1 Tg mice | A Hamilton micro syringe fixed on the stereotaxic apparatus was inserted 2.5 mm under the dura, and a 4 µL NSC suspension (at $1 \times 10^5$/µL) or PBS was injected into the brain gently | hNSCs | Alleviated cognitive, learning, and memory but not anxiety deficits in NOR and MWM tests | Transplantation of hNSC reduced soluble Aβs, but not insoluble Aβs and plaque burden in AD mice brains. Transplantation of hNSC rescued neuronal loss and connectivity in AD mice brains. Improved neuronal metabolic activity, elevated NAA and Glu peaks, but lowered choline and myo-inositol. |
| Authors                          | Models and Transgene                                      | Dosage and Injection Site                                                                 | Type of Stem Cells | Behavioral Outcome                                                                 | Mechanisms & Physiological Effects                                                                                                                                 |
|---------------------------------|-----------------------------------------------------------|------------------------------------------------------------------------------------------|--------------------|----------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1-6 Lee et al., 2015 [142]      | NSE/APPswe transgenic mice                                | One injection of 5 µL of vehicle or hNSC suspension 1 × 10^7 cells/µL bilaterally into lateral ventricles (LVs; 0.1 mm caudal, 0.9 mm bilateral to bregma, and 2.0 mm ventral from the dura mater) | hNSCs             | Spatial memory was improved in the MWM                                          | Human NSC transplantation inhibited tau phosphorylation, activated Trk-dependent Akt/GSK3β signaling, and reduced Aβ42 levels. Human NSC transplantation altered APP processing by modulating BACE1 expression, and decreased astrogliosis and microgliosis. Human NSC transplantation attenuated microglial activation through cell-to-cell contact and secretory molecules. Transplantation of hNSC reduced soluble Aβs, but not insoluble Aβs and plaque burden, in AD mice brains. |
| McGinley et al., 2018 [131]     | Male B6C3-Tg (APPswe/PSEN1ΔE9 85Dbo/J (APP/PS1; n = 20) mice (stock #034829-JAX; Jackson Laboratory, Bar Harbor, ME) | Unknown number of stem cell injected at the following coordinates (bregma/lateral/ventral): −0.82/0.75/2.5, −1.46/2.3/2.9, −1.94/2.8/2.9 mm | NSCs              | NSCs targeted to the fimbria fornix improved cognitive function in NOR and MWM tests | Transient NSC engraftment reduced Aβ plaque pathology. NSCs modulated microglial activation in vivo and in vitro.                                                                                                                                 |
| Ager et al., 2018 [143]         | APP/PS1 AD mouse model (8 weeks old)                     | 2-week interval with 3 × 10^5 cells per hippocampus                                        | NSCs              | NSCs targeted to the fimbria fornix improved cognitive function in NOR and MWM tests | Substantial survival of transplanted human cells in two distinct immunosuppressed transgenic models of AD-associated neurodegeneration. Increased synaptophysin (SYP), synapsin, and growth-associated protein-43 (GAP-43) in mice, indicating increased synaptic density. |
| Zhu et al., 2020 [144]          | APP/PS1 (APPswe, PSEN1ΔE9) double transgenic mice (5 months old) | One injection of 5 µL × (1 × 10^5 cells/µL) in the hippocampus bilaterally                   | NSCs derived from the embryonic brain (E12.5–14.5 days) of pregnant EGFP-labeled mice | Improved spatial learning and memory ability in the MWM | Engrafted stem cells survived and partly remained at the injection site. Some engrafted stem cells migrated to surrounding regions including the corpus callosum and adjacent cortex. Some engrafted stem cells experienced morphologic changes and differentiated into GFAP+ and DCX+ cells, i.e., astrocytes. SYP, PSD-95 (postsynaptic density protein 95), and MAP-2 proteins significantly increased after stem cell implantation. Neural stem cell transplantation increased ChAT protein levels in the basal forebrain. |

Abbreviations: hNSCs, human central nervous system stem cells; MWM, Morris water maze; GFAP, glial fibrillary acidic protein; DCX, doublecortin; SYP, synaptophysin; MAP-2, microtubule-associated protein 2; ChAT, choline acetyltransferase; SCID, severe combined immunodeficient; hAdMSCs, human adipose-derived mesenchymal stem cells; Ngn1, neogenin 1; BrdU, bromodeoxyuridine; hESCs, human embryonic stem cells; SHH, Sonic hedgehog; ISL1, insulin gene enhancer protein 1; OLIG2, oligodendrocyte transcription factor; ASCL1, achaete-scute family BHLH transcription factor 1; BMSCs, bone marrow-derived stem cells; NGF, nerve growth factor; BdnfIV, brain-derived neurotrophic factor IV; GRIN2B, glutamate ionotropic receptor NMDA type subunit 2B; NEP, neprilysin; IDE, insulin-degrading enzyme; NOR, novel object recognition test.
8. Clinical Studies of Stem Cell Implantation in Diseases Other Than AD

There have been many clinical studies of stem cell therapies for many kinds of disease, including spinal cord injury, Parkinson’s disease, and pancreatic beta cell insufficiency (diabetes mellitus). Although stem cell therapies show substantial promise, little success has been achieved in the treatment of many diseases. Five vital clinical studies have been chosen to evaluate the effectiveness of stem cells therapies in different diseases (Table 2).

A clinical trial on the use of human ES cells in congenital urea cycle disorder demonstrated therapeutic potential [145]. This was the world’s first clinical trial to use human ES cell-derived hepatocytes for the treatment of liver disease, which was verified to be both safe and effective. The patient, a 6-day-old baby with liver disease who was unable to detoxify ammonia, received ES cell injections into a blood vessel in the liver [145]. The implantation of ES cells was considered as a “bridge treatment” while the patient was waiting to receive a liver transplant 3 to 5 months after birth. After cell transplantation, there was no longer any increase in blood ammonia and the patient successfully completed the liver transplantation [145]. This study shows that stem cell therapy could be applied to prevent hyperammonemia while waiting for a liver transplantation. A study by Mendonça et al. investigated the effects of intralesional injection of bone marrow mesenchymal stem cells on spinal cord injury [146]. This Phase I trial observed inconsistent improvements in the sensitivity of all patients, with eight of them developing motor functioning in the lower limbs and seven of them improving their AIS. Although this study showed various improvements in patients, the sample size of 14 is too small to make a generalized conclusion [146]. A study on the effects of the umbilical cord blood-derived mesenchymal stem cells in patients with Parkinson’s disease was reviewed by Diáz in 2019 [147]. This ongoing study has not reported any outcome measurements or adverse effects so far, and the results need to be analyzed in the future. Other studies have shown that transducing stem cells with fibroblast growth factor-20 can increase their dopamine level to induce tyrosine carboxylase-positive cells [148].

A phase II study on the effects autologous bone marrow-derived stem cell transplantation on diabetes mellitus, reported by Bhansali et al., showed that the treatment ameliorated beta-cell functioning, as observed by a significant improvement in the glucagon-stimulated C-peptide levels and HOMA-B [149]. Moreover, the dosage requirement for insulin was also found to be decreased. There were no serious adverse effects, suggesting the stem cell treatment was safe, although the small study size is a concern and will require a larger study to verify the results [149]. A Phase I/II open-label study on the intrathecal transplantation of bone marrow-derived autologous mononuclear cells in 50 patients with Huntington’s disease showed improvement in cognitive and psychiatric symptoms, neuropsychiatric behaviors, writhing motions, abnormal posturing, and increased life expectancy [150]. Due to its large sample size, these results should be generalizable to the wider population of patients with Huntington’s disease [150]. As no information was given regarding any adverse reactions, its safety should be considered before clinical use.
### Table 2. Present clinical studies of stem cell therapies in diseases.

| Authors                      | Disease, Clinical Phase, and Duration | Study Design                      | Type of Stem Cells and Implantation Route | Dosage and Concentration | Outcome Measures                                                                 | Clinical Evaluation                                                                 | Adverse Effects                                                                 |
|------------------------------|--------------------------------------|-----------------------------------|------------------------------------------|--------------------------|----------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| 1-8 “Clinical trial with human...” [145] | Congenital Urea Cycle Disorder Phase N.A. | 6-day-old baby                    | Human embryonic stem (HES) cell-derived hepatocytes Intravenous infusion | N.A.                     | Blood ammonia concentration                                                      | Liver transplantation                                                              | No complications from the surgical procedure.                                       |
| Mendonça et al., 2014 [146]  | Spinal Cord Injury Phase 1 6 months  | Open-label, single-group assignment 14 patients (18 to 50 years old) | Bone marrow mesenchymal stem cells (BMMSC) Intralesional injection | $5 \times 10^6$ cells/cm³ single dose | Feasibility and Safety of BMMSC, Functional Improvement in muscle strength and sphincter control | Frankel Scale American Spinal Injury Association Impairment Scale (AIS) Somatosensory evoked potential (SEP) | One patient developed cerebrospinal fluid (CSF) leak due to intervention practices. No severe side effects or other complications. |
| Díaz, 2019 [151]            | Parkinson’s Disease Phase 1 1 year   | Open-label, single-group assignment 20 participants (40 to 60 years old) | Umbilical cord blood-derived mesenchymal stem cells (UC-MSCs) Intravenous infusion | 10–20 million cells once a week for 3 weeks | N.A. | Improvement in psychiatric symptoms Increased life expectancy Improvement in writhing or abnormal posturing | Unified Parkinson’s Disease Rating Scale (UPDRS) MMSE Hoehn and Yahr staging (H-Y) Hamilton Depression Scale 24 (HAMD 24) Hamilton Anxiety Scale 14 (HAMA-14) | N.A. |
| Bhansali et al., 2009 [149] | Diabetes Mellitus Phase II 6 months | Open-label, single-group assignment 10 patients (30 to 75 years old) | Autologous bone marrow-derived stem cells (ABMSCs) Angiographically | N.A. | Reduction of insulin requirement by > 50% Increment in glucagon stimulated C-peptide levels Reduction of insulin requirement Improvement of HbA1c levels compared to baseline | Glucagon stimulated C-peptide levels Insulin dosage HbA1c levels | No serious adverse effects were noted. |
| Rodrigues & Edward, 2018 [150] | Huntington’s Disease Phase 1/II 36 months | Open-label, single-group assignment 50 participants (35 to 44 years old) | Bone marrow-derived autologous mononuclear cells (BMAMNCs) Intrathecal transplantation | 100 million stem cells per dose | Improvement in cognitive and psychiatric symptoms Improvement in neuropsychiatric behavior Improvement in writhing motions or abnormal posturing Improvement in compulsive behavior | N.A. | N.A. |

Current clinical studies of stem cell therapies in diseases other than AD. Abbreviations: human embryonic stem cells; BMMSCs, bone marrow mesenchymal stem cells; AIS, American Spinal Injury Association Impairment Scale; SSEP, somatosensory evoked potential; CSF, cerebral spinal fluid; UC-MSCs, umbilical cord blood-derived mesenchymal stem cells; UPDRS, Unified Parkinson’s Disease Rating Scale; MMSE, Mini Mental State Examination; H-Y staging, Hoehn and Yahr staging; HAMD 24, Hamilton Depression Scales 24; HAMA-14, Hamilton Anxiety Scale 14; ABMSCs, autologous bone marrow-derived stem cells; HbA1c, glycated hemoglobin; BMAMNCs, bone marrow-derived autologous mononuclear cells; N.A., not available.
9. Clinical Research on Stem Cell Therapies in AD

Although the concept of stem cell therapy has been around for more than 20 years, clinical trials investigating their effects in AD patients have been limited due to ethical issues, hindering their development as a treatment for AD [152]. Six clinical trials on stem cell-based therapies in AD are reviewed (Table 3).

The various cell therapies in the six clinical trials reviewed all used MSCs, which were derived from different tissues. The stem cells used in these clinical trials were mostly administered via the intravenous route, while stem cell transplantation in one trial was performed through surgical incision. The wide use of MSCs in many studies is due to their reported viability, safety, and efficacy [153]. Previous studies showed MSCs have tissue-regenerative properties, paracrine effects on the microenvironment, and immunomodulatory ability without causing immunological rejection in xeno-transplantation and allo-transplantation. As extensive research has been conducted on the efficacy and safety of MSCs, their use in clinical trials should accelerate the advancement of stem cell therapy for AD.

The first clinical trial investigating the effect of implanted stem cells in AD was conducted in 2011 by scientists at Medipost Co Ltd., Shandong China [154]. This phase 1 trial focused on the safety and efficacy of using human umbilical cord blood-derived MSCs (hUC-MSC). They investigated dose-limiting toxicity of hUC-MSC injection in patients with mild-to-moderate AD. The clinical effectiveness of neural stem cells in treating AD patients was also not reported by Medipost Co Ltd. Moreover, several adverse effects were observed during the 12-week follow-up period. There were reports of acute adverse symptoms such as hearing discomfort, headaches, and dizziness, but there were no severe complications. This study also had several limitations including only nine patients and short follow-up period, and the design of this clinical trial was not an open-label trial. Such blinded studies can lead to the risk of placebo effects, as they are prone to psychogenic bias [155]. For example, patients with AD could be aware that they have received stem cell therapy, or their relatives could mention or ask them about their treatment, which could bias the experimental results.

In 2011, Ra et al. investigated the safety of human adipose tissue-derived mesenchymal stem cell infusion in both humans and animals [135]. The preclinical part of this study has already been discussed above. In their clinical trial, spinal cord injury patients between the ages of 23 and 54 with differing symptoms (seven quadriplegic and one paraplegic) were included in the study. There were no significant differences in the post-injection laboratory findings, physical examination, vital signs, and electrocardiogram, although there were some improvements in spinal cord injury after the neural stem cell treatment. They found the average area of spine damage was decreased from $134.50 \pm 95.69 \text{ mm}^2$ to $122.93 \pm 99.45 \text{ mm}^2$ after 12 weeks. Overall, 19 adverse events were observed including chest pain, chest tightness, and mild fever, although none of the patients developed any serious complications. Besides the adverse events from the stem cell therapy, the study sample was also too small, and the observational period was too short (26 weeks); additionally, they did not include AD patients [135]. Another clinical open-label study by Niu et al. with a longer follow-up of up to a year had a better study design and provided details of the protocols [156]. A more recent clinical trial by Oliva et al. [157] was a double-blind, randomized, placebo-controlled Phase I clinical trial. This study showed a newly developed stem cell, Longeveron allogenic mesenchymal stem cell, (LMSCs) was highly safe and tolerable. Recently, Liu et al. [20] reported two ongoing studies, one using umbilical cord-derived allogeneic hMSCs intravenously and the other using bone marrow stem cells (BMSCs) intravenously, intranasally, and with near-infrared light. These studies are currently recruiting, and their findings will need to be analyzed in the future. Although the use of stem cells in AD patients have shown relatively good results and are generally safe and tolerable, their efficacy in humans has yet to be established.
Table 3. Clinical studies investigating the effectiveness or safety of stem cell therapies in AD patients.

| Authors          | Clinical Phase & Duration | Study Design                  | Type of Stem Cells and Implantation Route | Dosage and Concentration | Outcome Measures | Clinical Evaluation                                                                 | Adverse Effects               |
|------------------|---------------------------|-------------------------------|------------------------------------------|--------------------------|-----------------|--------------------------------------------------------------------------------------|------------------------------|
| Liu et al. [20]  | Phase I active 65 weeks   | Open-label, prospective, single-group assignment 50 to 85 years old | Umbilical cord-derived, allogeneic hMSCs Intravenous infusion | 100 million cells per infusion | N.A.             | Adverse events evaluation                                                                 | N.A.                         |
|                  |                           |                               |                                          |                          |                 | ADAS-Cog                                                                                   |                              |
|                  |                           |                               |                                          |                          |                 | MMSE                                                                                      |                              |
|                  |                           |                               |                                          |                          |                 | Geriatric Depression Scale (GDS)                                                         |                              |
|                  |                           |                               |                                          |                          |                 | Odor identification test                                                                  |                              |
| Oliva et al., 2019 [157] | Phase I completed Active for Phase II 1 year | Randomized controlled trial 50 to 80 years old | Longeveron MSCs Intravenous infusion | Once for 20 million LMSCs (low-dose), 100 million LMSCs (high-dose), or placebo | N.A.             | Cognitive assessments                                                                 | No serious adverse events |
|                  |                           |                               |                                          |                          |                 | Patient-reported outcomes (PROs)                                                          |                              |
|                  |                           |                               |                                          |                          |                 | Biomarkers (serum, CSF, and MRI).                                                         |                              |
| Ra et al., 2011 [135] | Phase 1 7 months       | Single group 8 male patients (19 to 60 years old) | Autologous adipose-derived MSCs Intravenous infusion | $4 \times 10^8$ autologous hAdMSCs per patient | Improvement in some of the cases | Blood chemistry, HBV/HCV, hematology, and urinalysis, and were screened for HIV, and VDRL. A pulmonary function test, chest X-ray, spinal cord independence measure (SCIM), visual analog scale, electrophysiological examination of motor, spinal magnetic resonance imaging, somatosensory evoked potentials (MEP and SEP, respectively), and neurological examinations using ASIA were obtained for each patient. | 19 adverse events were observed in 8 patients, including chest tightness, chest pain, and mild fever. |
### Table 3. Cont.

| Authors              | Clinical Phase & Duration | Study Design                                      | Type of Stem Cells and Implantation Route             | Dosage and Concentration                                           | Outcome Measures | Clinical Evaluation                        | Adverse Effects             |
|----------------------|---------------------------|---------------------------------------------------|------------------------------------------------------|--------------------------------------------------------------------|------------------|---------------------------------------------|--------------------------|
| 1-8 Niu et al., 2016 | Phase I/II Active 1 year  | Open-label, self-control, single-center prospective trial 30 patients (50 to 83 years old) | hUC-MSCs Intravenous into the median cubital vein | $0.5 \times 10^6$ hUC-MSCs/kg                                        | N.A.             | Adverse effects evaluation                  | AD improvement, e.g., CIBIC, MMSE, ADL, and NPI | N.A.                    |
| Medipost Co Ltd.     | Phase I N.A.              | Open-label, single-group assignment 9 patients (50 to 75 years old) | Human umbilical cord blood-derived MSCs              | Dose A—250,000 cells per 5 µL per entry site, 3 million cells per brain Dose B—500,000 cells per 5 µL per entry site, 6 million cells per brain | N.A.             | Adverse event evaluation                    | Changes in ADAS-cog       | N.A.                    |
| Liu et al. [20]      | Phase N.A. 12 months      | Open-label, non-randomized, parallel assignment 18 years and older | Bone marrow stem cells (BMSCs) 1. Intravenous fraction 2. Intrasal topical fraction 3. Near-infrared light | 1. 14 cc of BMSC fraction 2. 1 cc of BMSC fraction 3. 14 cc of BMSC fraction | N.A.             | MMSE Autism Spectrum Quotient Exam (AQ)    | ADCS-ADL                 | N.A.                    |

Clinical studies investigating the effectiveness or safety of stem cell therapies in AD patients. Abbreviations: hUC-MSCs, human umbilical cord blood-derived mesenchymal stem cells; ADAS-Cog, AD Assessment Scale-cognitive Subscale; S-IADL, Seoul Instrumental Activities of Daily Living; MMSE, Mini Mental State Examination; hMSCs, human mesenchymal stem cells; GDS, Geriatric Depression Scale; ADRQL-40, Alzheimer’s Disease Related Quality of Life; ADCS-ADL, AD Cooperative Study Activities of Daily Living; NPI-Q, Neuropsychiatric Inventory-Q; LMSCs, Longeveron mesenchymal stem cells; PROs, patient-reported outcomes; CSF, cerebral spinal fluid; MRI, magnetic resonance imaging; hAdMSCs, human adipose-derived mesenchymal stem cells; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; VRDL, venereal disease research laboratory test; SCIM, spinal cord independence measure; MEP, motor evoked potential; SEP, sensory evoked potential; ASIA, American Spinal Injury Association; CIBIC, Clinician Interview-Based Impression of Change; ADL, Activities of Daily Living; NPI, Neuropsychiatric Inventory; BMSCs, bone marrow stem cells; hESCs, human embryonic stem cells; AQ, Autism Spectrum Quotient Exam; N.A., not available.
10. Mechanisms of Stem Cell Therapy in AD

In recent years, MSCs, ESCs, iPSCs, and brain-derived NSCs have been used in stem cell research in AD [20]. Embryonic stem cells are derived from the inner cell mass of pluripotent blastocysts [158]. They are pluripotent and can generate all cell types including mesodermal, endodermal, and ectodermal cells. However, their clinical application has been limited due to immune rejection and possible teratoma formation. Therefore, other types of stem cells such as MSCs have been used for stem cell therapy in AD [159]. A review paper by Liu et al. established the effectiveness of MSCs over ESCs in improving spatial learning and preventing memory decline [20]. On the contrary, Wang et al. showed that ESCs could improve mental aptitude in AD rodent models [116]; hence, the use of ESC in treating AD cannot be completely disregarded.

There is a growing number of studies showing the effectiveness of stem cell therapies in AD patients. However, the mechanisms underlying their effectiveness are not fully established. A study conducted by Zhu et al. in 2020 [144] showed that after engraftment of neural stem cells, some cells remained at the injection site, whereas some cells migrated to surrounding regions in the brain such as the corpus colosum. Cells were labeled with glial fibrillary acidic protein (GFAP) and doublecortin (DCX) to observe their differentiation into either astrocytes or other neurons. A small amount of the neural stem cells was observed to differentiate into astrocytes, whereas most differentiated into DCX+ neurons. These findings show that neural stem cells have the ability to both differentiate and migrate to facilitate repair of AD rodent brain. This finding was also supported in a study by Li et al., which showed stem cells could be differentiated into choline acetyltransferase (ChAT)-like neurons, supporting cognition [137]. Zhu et al. also reported that NSC transplantation increased levels of SYP, MAP-2, and SYP proteins. These proteins, especially MAP-2, are involved in microtubule assembly and are found at higher levels in dendrites [160]. The increased protein levels suggest that neural stem cells can increase neurogenesis. The NSC transplants also increased the level of ChAT neurotransmitters in the forebrain, indicating the NSCs also play a role in protecting cholinergic neurons. To investigate how NSCs can enhance neurogenesis, a study conducted by Se et al. examined the Wnt signaling pathway in a mouse model treated with NSCs [136]. They found MSC implantation increased the expression levels of GFAP, SOX2, Ki-67, HuD, and nestin, suggesting that NSCs can enhance neurogenesis possibly through the Wnt signaling pathway. Another study by Nakano et al. demonstrated that the implantation of bone marrow-derived MSCs in the hippocampus enhanced cognitive function through increasing the expression of microRNA-146a in AD rodent models [139]. To further investigate how the increased expression of microRNA-146a improved cognitive function, tissue sections were stained with synaptic marker (synaptophysin) to examine the synaptic density. They found AD rodents had increased synaptic density, confirming that microRNA-146a can induce synaptogenesis. As astrocytes were also reported to have a role in synaptogenesis [161], Nakano et al. further investigated the relationship between microRNA-146a, astrocytes, and synaptogenesis. They found that bone marrow-derived MSC exosomes containing miRNA-146a were taken up by astrocytes. They concluded that miRNA-146a was absorbed into astrocytes prompting synaptogenesis, leading to improved cognitive functions in AD rodents. However, how miRNA-146a is taken up by astrocytes leading to synaptogenesis is still unclear.

Stem cells were previously shown to alter the concentration of amyloid-β and tau, leading to cognitive improvements in AD. However, a study by Jones et al. [162] showed that stem cells increased synaptic density in the brain via BDNF, rather than directly altering amyloid-β and tau levels. These findings support the studies by Nakano et al. and Ager et al. [143]. Coming full circle, recent studies have reestablished support for the previous view that stem cells can reduce both amyloid-β and tau levels, leading to enhanced cognitive function. Recent studies in the past 5 years from Chen et al., Li et al., Lee et al., McGinley et al., and Lu et al. showed that MSC implantation could reduce levels of amyloid-β, leading to improved cognition in mice [131,138,140,142]. In addition to stem cells modulating BACE1 expression to alter APP processing, Lee et al. also showed that
stem cell transplantation could inhibit tau phosphorylation. They found that stem cells reduced tau phosphorylation through the activation of the Trk-dependent Akt/GSK3β signaling pathway [142].

A study by Lu et al. suggested stem cell implantation could reduce amyloid-β 40 and 42 accumulation by a clearance mechanism involving increased IDE and NEP levels [140]. A study by Chen et al. showed stem cells prevented the downregulation of BDNF, which further supports the studies by Jones et al., Nakano et al., and Ager et al. [138,139,143,162]. Neuronal memory and synaptic plasticity-related genes, such as BDNF, SYP, GluR2, and GRIN2B, have been shown to improve memory. Moreover, Chen also showed that MSC-exosomes could improve brain glucose metabolism as measured by [18F] FDG-PET. Abnormal expression of HDAC4 was decreased after the treatment, whereas the expressions of HDAC4 target genes like Homer protein homolog 1, synapsin II, and leucine-rich glioma inactivated 1 were increased, leading to amelioration of learning and memory deficits [138].

Lu et al. also reported the effects of stem cell treatment in AD involving neuroinflammation and pericytes [140]. They discovered that hNSC transplantation could reduce the density of astrocytes and microglia, suggesting the inhibition of neuroinflammation leading to improved cognition. A study by McGinley et al. also supported the modulation of microglial activation in vivo [68]. Lu et al. found that hNSC transplantation enhanced endogenous neurogenesis, while reducing pericytic and synaptic loss in the hippocampus of APP/PS1 mice. They suggested the increase in pericytes enhanced amyloid-β clearance by facilitating phagocytosis and transport out of the CNS across the BBB, while maintaining BBB permeability, oxygen supply, and metabolites in collaboration with endothelial cells. Pericytes were also found to modulate neurogenesis and angiogenesis, with corresponding changes in cognition. Last but not the least, Li et al. revealed that hNSC transplantation elevated NAA and Glu levels and lowered choline and myo-inositol levels, leading to improved neuronal activity (Figure 1).
Figure 1. Mechanism of stem cell amelioration of cognition. Stem cells enhance formation of Syt, PSD-95, and MAP2, which can stimulate synaptogenesis. miRNA-146a is also secreted by stem cells and later taken up by astrocytes, leading to synaptogenesis. Stem cells can increase cholinergic neuron production in three ways: 1. increased Trk-dependent Akt/Gsk3β signaling, 2. differentiation into cholinergic cells, and 3. increased secretion of Ki-67, GFAP, SOX2, nestin, and HuD; increased secretion of β-catenin and neurogenin (Ngn); and increased production of cholinergic cells. Brain glucose metabolism is also increased after stem cell implantation through increased N-acetylaspartate (NAA) and glutamate secretion and decreased choline and myo-inositol secretion. Amyloid-β40 & 42 are known to cause AD. Stem cells can alter APP processing through Akt/GSK3β signaling-mediated BACE1 expression and decrease β-secretase activity to decrease amyloid β concentration and improve cognition. Pericytes also have a role in AD. Transplantation of stem cells can inhibit pericyte loss to: 1. promote phagocytosis of amyloid-β, 2. transport amyloid-β across the BBB, 3. supply oxygen and metabolites to endothelial cells, and 4. increase angiogenesis and neurogenesis, which improves cognitive function. Stem cells have a potent effect on tau phosphorylation in AD. They decrease tau phosphorylation, leading to increased microtubule stabilization and healthier neurons, thereby ameliorating cognition [141].
11. Limitations and Future Perspectives

As the research on stem cells has progressed, several limitations on the use of stem cells in AD have been revealed. In 1988, Date et al. [163] explored the issue behind the immune rejection of stem cells when transplanted into the body. Although they did not specifically study AD rodent models, they found that NSC grafts resulted in class I MHC antigens on the newly developed neuronal tissue. They also observed increased numbers of reactive astrocytes in the graft, indicating immune rejection activities. In earlier studies [116], it was found that after implantation of ESCs, the grafted cells developed into a teratoma. Subsequently, other types of stem cells such as MSCs have been used, which have a lower chance of developing into a teratoma. Although the stem cells developed by Medipost Ltd. Co. were reported to be safe against immune rejection, future studies will be needed to confirm their safety in humans. Several ethical concerns need to be considered when using stem cells [164]. For example, it can be difficult to obtain permission to treat infants with embryonic tissues such as stem cells. Another concern by Tan et al. is that the authenticity of the patient may be threatened after stem cell implantation, as they may believe the treatment might enhance or change the retention of particular memories [165].

In the brain, the complex neural circuits play a role in so-called higher brain functions. The transplanted stem cells have the potential to not only decrease neural damage, but also to alter neural circuits. The treatment of patients with mild or severe Alzheimer’s disease may lead to completely different personalities through the generation of new neural pathways. Tan et al. also suggested that some unwanted consequences may occur, such as the overgeneralization of enhanced memories that could lead to anxiety disorders. A study by Aguila et al. indicated another limitation could be the complexity of the cellular programming and reprogramming of stem cells. For example, the functionality of stem cells might be affected by intrinsic factors or by abnormal extrinsic factors like Wnt1, Fgf8, and retinoic acid [166]. Therefore, researchers need to conduct more studies to ensure the intact functionality of the transplanted stem cells.

12. Conclusions

Alzheimer’s disease affects millions of individuals globally every year and is becoming an increasing health burden. Although various therapeutic treatments for AD are available such as cholinesterase inhibitors, memantine, NMDA receptor antagonists, and antioxidants, their effectiveness are low. Stem cell therapy as a potential treatment for AD has sparked the interest of many scientists. Research on human neural stem cells has greatly increased in recent years, demonstrating their potential beneficial effects. Over the years, many preclinical studies have been conducted to investigate the effectiveness of stem cells in AD. Preclinical studies of stem cell treatments in rodent AD models have successfully shown they can improve cognitive functions. However, more clinical trials are needed to establish their effectiveness and safety in humans. As the main goal of AD treatments is to cure AD or slow down disease progression, more research is needed to maximize the effectiveness of stem cells. Even if stem cells are proven to be useful in combating AD, there are also hurdles in generalizing this therapy due to their prohibitive cost.

This review has some weaknesses as only a few highly relevant studies were included, and the scope of the study did not allow us to comprehensively compare all trials. Moreover, the review does not present a full analysis of all of stem cell developments in AD, although this review includes many up-to-date studies. Considering the reviewed studies, we can foresee more research will emerge in this field, providing useful insights on the administration route, combination therapies, and human applications in the future.

Author Contributions: Conceptualization and study design, funding/resources, data analysis, supervision, and revision: L.W.L. Original draft preparation, revision, data analysis, and preparation of figures: H.J.C and Y. Analysis and revision: J.R. Analysis, supervision, and revision: G.L.T and M.-L.F. All authors have contributed substantially to the intellectual inputs. All authors have read and agreed to the published version of the manuscript.
References

1. Kumar, A.; Sidhu, J.; Goyal, A.; Tsao, J.W. Alzheimer Disease. In StatPearls; StatPearls Publishing LLC.: Treasure Island, FL, USA, 2021.
2. Balázs, N.; Kovács, T. Heterogeneity of Alzheimer’s disease. Orv. Hetil. 2021, 162, 970–977. [CrossRef] [PubMed]
3. Emmady, P.D.; Tadi, P.; Del Pozo, E. Dementia (Nursing). In StatPearls; StatPearls Publishing LLC.: Treasure Island, FL, USA, 2021.
4. Ganguli, M.; Hendrie, H.C. Screening for cognitive impairment and depression in ethnically diverse older populations. Alzheimer Dis. Assoc. Disord. 2005, 19, 275–278. [CrossRef] [PubMed]
5. Yuan, J.; Zhang, Z.; Wen, H.; Hong, X.; Hong, Z.; Qu, Q.; Tang, M.; Wu, J.; Xu, Q.; Li, H.; et al. Incidence of dementia and subtypes: A cohort study in four regions in China. Alzheimers Dement. 2016, 12, 262–271. [CrossRef] [PubMed]
6. Burns, A.; Iliffe, S. Alzheimer’s disease. BMJ 2009, 338, b158. [CrossRef] [PubMed]
7. Guerreiro, R.; Bras, J. The age factor in Alzheimer’s disease. Genome Med. 2015, 7, 106. [CrossRef]
8. Bennett, S.; Thomas, A.J. Depression and dementia: Cause, consequence or coincidence? Maturitas 2014, 79, 184–190. [CrossRef]
9. Tanaka, M.; Vecsei, L. Editorial of Special Issue “Crosstalk between Depression, Anxiety, and Dementia: Comorbidity in Behavioral Neurology and Neuropsychiatry”. Biomedicines 2021, 9, 517. [CrossRef]
10. Soria Lopez, J.A.; Gonzalez, H.M.; Léger, G.C. Chapter 13—Alzheimer’s disease. In Handbook of Clinical Neurology; Dekosky, S.T., Asthana, S., Eds.; Elsevier: Amsterdam, The Netherlands, 2019; pp. 231–255.
11. Riedel, B.C.; Thompson, P.M.; Brinton, R.D. Age, APOE and sex: Triad of risk of Alzheimer’s disease. J. Steroid Biochem. Mol. Biol. 2016, 160, 134–147. [CrossRef]
12. Pike, C.J. Sex and the development of Alzheimer’s disease. J. Neurosci. Res. 2017, 95, 671–680. [CrossRef]
13. Pines, A. Alzheimer’s disease, menopause and the impact of the estrogenic environment. Climacteric 2016, 19, 430–432. [CrossRef]
14. Davey, D.A. Alzheimer’s disease, dementia, mild cognitive impairment and the menopause: A ‘window of opportunity’? Womens Health 2013, 9, 279–290. [CrossRef]
15. Scheyer, O.; Rahman, A.; Hristov, H.; Berkowitz, C.; Isaacsen, R.S.; Diaz Brinton, R.; Mosconi, L. Female Sex and Alzheimer’s Risk: The Menopause Connection. J. Prev. Alzheimers Dis. 2018, 5, 225–230. [CrossRef]
16. Rettberg, J.R.; Dang, H.; Hodis, H.N.; Henderson, V.W.; St John, J.A.; Mack, W.J.; Brinton, R.D. Identifying postmenopausal women at risk for cognitive decline within a healthy cohort using a panel of clinical metabolic indicators: Potential for detecting an at-Alzheimer’s risk metabolic phenotype. Neurobiol. Aging 2016, 40, 155–163. [CrossRef] [PubMed]
17. Mosconi, L.; Rahman, A.; Diaz, I.; Wu, X.; Scheyer, O.; Hristov, H.W.; Vallabhajosula, S.; Isaacsen, R.S.; de Leon, M.J.; Brinton, R.D. Increased Alzheimer’s risk during the menopause transition: A 3-year longitudinal brain imaging study. PLoS ONE 2018, 13, e0207885. [CrossRef]
18. Sini, P.; Dang, T.B.C.; Fais, M.; Galioto, M.; Padedda, B.M.; Lugliè, A.; Iaccarino, C.; Crosio, C. Cyanobacteria, Cyanotoxins, and Neurodegenerative Diseases: Dangerous Liaisons. Int. J. Mol. Sci. 2021, 22, 8726. [CrossRef] [PubMed]
19. WHO. Dementia Fact Sheet 2020; WHO: Geneva, Switzerland, 2020; Available online: https://www.who.int/news-room/fact-sheets/detail/dementia (accessed on 22 June 2021).
20. Liu, X.-Y.; Yang, L.-P.; Zhao, L. Stem cell therapy for Alzheimer’s disease. World J. Stem Cells 2020, 12, 787–802. [CrossRef]
21. Boese, A.C.; Hamblin, M.H.; Lee, J.P. Neural stem cell therapy for neurovascular injury in Alzheimer’s disease. Exp. Neurol. 2020, 324, 113112. [CrossRef] [PubMed]
22. Barati, M.; Akhoundi, M.; Mousavi, N.S.; Haghparast, N.; Ghodsí, A.; Baharvand, H.; Ebrahimi, M.; Hassani, S.N. Pluripotent Stem Cells: Cancer Study, Therapy, and Vaccination. Stem Cell Rev. Rep. 2021, 1–18. [CrossRef]
23. Wei, M.; Li, S.; Le, W. Nanomaterials modulate stem cell differentiation: Biological interaction and underlying mechanisms. J. Nanobiotechnol. 2017, 15, 75. [CrossRef]
24. Montine, T.J.; Phelps, C.H.; Beach, T.G.; Bigio, E.H.; Cairns, N.J.; Dickson, D.W.; Duyckaerts, C.; Frosch, M.P.; Masliah, E.; Mirra, S.S. et al. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: A practical approach. Acta Neuropathol. 2012, 123, 1–11. [CrossRef]
25. Masliah, E.; Terry, R.D.; Mallory, M.; Alford, M.; Hansen, L.A. Diffuse plaques do not accentuate synapse loss in Alzheimer’s disease. Am. J. Pathol. 1990, 137, 1293–1297.
26. Masliah, E.; Mallory, M.; Deerinck, T.; Deeresa, R.; Lamont, S.; Miller, A.; Terry, R.D.; Carragher, B.; Ellisman, M. Re-evaluation of the structural organization of neuritic plaques in Alzheimer’s disease. J. Neuropathol. Exp. Neurol. 1993, 52, 619–632. [CrossRef] [PubMed]

27. Braak, H.; Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82, 239–259. [CrossRef] [PubMed]

28. Wong, K.Y.; Roy, J.; Fung, M.L.; Heng, B.C.; Zhang, C.; Lim, L.W. Relationships between mitochondrial dysfunction and neurotransmission failure in Alzheimer’s disease. Aging Dis. 2020, 11, 1291. [CrossRef]

29. Fillenbaum, G.G.; van Belle, G.; Morris, J.C.; Mooh, R.C.; Mirra, S.S.; Davis, F.C.; Tariot, P.N.; Silverman, J.M.; Clark, C.M.; Welsh-Bohmer, K.A.; et al. Consortium to Establish a Registry for Alzheimer’s Disease (CERAD): The first twenty years. Alzheimers Dement. 2008, 4, 96–109. [CrossRef] [PubMed]

30. Mihardja, M.; Roy, J.; Wong, K.Y.; Aquilli, L.; Heng, B.C.; Chan, Y.S.; Fung, M.L.; Lim, L.W. Therapeutic potential of neurogenesis and melatonin regulation in Alzheimer’s disease. Ann. N. Y. Acad. Sci. 2020, 1478, 43–62. [CrossRef] [PubMed]

31. Nilserth, C.; Westlid-Danielsson, A.; Eckman, C.B.; Condron, M.M.; Axelam, K.; Forsell, C.; Stenl, C.; Luthman, J.; Teplow, D.B.; Younkin, S.G.; et al. The ‘Arctic’ APP mutation (E693G) causes Alzheimer’s disease by enhanced Abeta protofibril formation. Nat. Neurosci. 2001, 4, 887–893. [CrossRef]

32. Tomiyama, T.; Shimada, H. APP Osaka Mutation in Familial Alzheimer’s Disease-Its Discovery, Phenotypes, and Mechanism of Recessive Inheritance. Int. J. Mol. Sci. 2020, 21, 1413. [CrossRef]

33. Hur, J.Y.; Frost, G.R.; Wu, X.; Crump, C.; Pan, S.J.; Wong, E.; Barros, M.; Li, T.; Nie, P.; Zhai, Y.; et al. The innate immunity protein IFITM3 modulates γ-secretase in Alzheimer’s disease. Nature 2018, 563, 735–740. [CrossRef] [PubMed]

34. Armstrong, R.A. What causes Alzheimer’s disease? Folia Neuropathol. 2013, 51, 169–188. [CrossRef]

35. Gremer, L.; Schölzel, D.; Schenk, C.; Reintertz, E.; Labahn, J.; Ravelli, R.B.G.; Tusche, M.; Lopez-Iglesias, C.; Hoyer, W.; Heise, H.; et al. Fibril structure of amyloid-β(1-42) by cryo-electron microscopy. Science 2017, 358, 116–119. [CrossRef]

36. Murphy, M.P.; LeVeine, H., 3rd. Alzheimer’s disease and the amyloid-beta peptide. J. Alzheimer Dis. JAD 2010, 19, 311–323. [CrossRef]

37. Makin, S. The amyloid hypothesis on trial. Nature 2018, 559, 54–57. [CrossRef]

38. Stern, Y. Cognitive reserve in ageing and Alzheimer’s disease. Lancet Neurol. 2012, 11, 1006–1012. [CrossRef]

39. Hamano, T.; Enomoto, S.; Shirafuji, N.; Ikawa, M.; Yamamura, O.; Yen, S.H.; Nakamoto, Y. Autophagy and Tau Protein. Int. J. Mol. Sci. 2021, 22, 7475. [CrossRef]

40. Adams, J.D. Probable Causes of Alzheimer’s Disease. Science 2021, 3, 16. [CrossRef]

41. Ma, K.; Ding, X.; Song, Q.; Han, Z.; Yao, H.; Ding, J.; Hu, G. Lactate enhances Arc/arg3.1 expression through hydroxycarboxylic acid receptor 1-β-arrestin2 pathway in astrocytes. Neuropsychopharmacology 2020, 171, 108084. [CrossRef]

42. Freitas, H.R.; Isaac, A.R.; Malcher-Lopes, R.; Diaz, B.L.; Trevenzo, I.; De Melo Reis, R.A. Polyunsaturated fatty acids and endocannabinoids in health and disease. Nutr. Neurosci. 2018, 21, 695–714. [CrossRef] [PubMed]

43. Jafari Nasabian, P.; Inglis, J.E.; Reilly, W.; Kelly, O.J.; Ilich, J.Z. Aging human body: Changes in bone, muscle and body fat with consequent changes in nutrient intake. J. Endocrinol. 2017, 234, R37–R51. [CrossRef] [PubMed]

44. Spencer, S.J.; Korosi, A.; Layé, S.; Shukitt-Hale, B.; Barrientos, R.M. Food for thought: How nutrition impacts cognition and emotion. NPJ Sci. Food Emotion 2017, 1, 7. [CrossRef]

45. Dyall, S.C. Interplay Between n-3 and n-6 Long-Chain Polyunsaturated Fatty Acids and the Endocannabinoid System in Brain Protection and Repair. Lipids 2017, 52, 10084. [CrossRef]

46. McGrattan, A.M.; McGuinness, B.; McKinley, M.C.; Kee, F.; Passmore, P.; Woodside, J.V.; McEvoy, C.T. Diet and Inflammation in Cognitive Ageing and Alzheimer’s Disease. Curr. Nutr. Rep. 2019, 8, 53–65. [CrossRef]

47. Morris, M.C.; Tangney, C.C.; Wang, Y.; Sacks, F.M.; Barnes, L.L.; Bennett, D.A.; Aggarwal, N.T. MIND diet slows cognitive decline with aging. Alzheimers Dement. 2015, 11, 1015–1022. [CrossRef]

48. Yuyama, K.; Matthews, S.; Mitusuka, S.; Igarashi, Y. Pathological roles of ceramide and its metabolites in metabolic syndrome and Alzheimer’s disease. Biochim. Biophys. Acta BBA—Mol. Cell. Biol. Lipids 2014, 1841, 793–798. [CrossRef]

49. Adams, J.D., Jr. DNA, Nuclear Cell Signaling and Neurodegeneration. In Extracellular and Intracellular Signaling; Royal Society of Chemistry: London, UK, 2011; pp. 155–187. [CrossRef]

50. Adams, J.D., Jr.; Lien, E.J.; Parker, K. Extracellular and Intracellular Signaling—A New Approach to Diseases and Treatments. In Extracellular and Intracellular Signaling; Royal Society of Chemistry: London, UK, 2011; pp. 1–9. [CrossRef]

51. Adams, J.; James, D. Alzheimer’s disease, ceramide, visfatin and NAD. CNS Neurol Drug Disc Targets 2008, 7, 492–498. [CrossRef]

52. Adams, J. The Treatment of Brain Inflammation in Alzheimer’s Disease. Can Traditional Medicines Help? Front. Clin. Drug Res.—Alzheimer Disord. 2017, 6, 1.

53. Tanaka, M.; Toldi, J.; Vecsei, L. Exploring the Etiological Links behind Neurodegenerative Diseases: Inflammatory Cytokines and Bioactive Kynurenines. Int. J. Mol. Sci. 2020, 21, 2431. [CrossRef] [PubMed]

54. Lautert, K.L.; Rajaram, R.D.; Herrmann, N. Therapy for Alzheimer’s Disease: How Effective are Current Treatments? Ther. Adv. Neurol. Disord. 2009, 2, 163–180. [CrossRef] [PubMed]

55. Salomone, S.; Caraci, F.; Leggio, G.M.; Fedotova, J.; Drago, F. New pharmacological strategies for treatment of Alzheimer’s disease: Focus on disease modifying drugs. Br. J. Clin. Pharmacol. 2012, 73, 504–517. [CrossRef] [PubMed]
56. Rijpma, A.; Meulenbroek, O.; Olde Rikkert, M.G. Cholinesterase inhibitors and add-on nutritional supplements in Alzheimer’s disease: A systematic review of randomized controlled trials. *Ageing Res. Rev.* **2014**, *16*, 105–112. [CrossRef] [PubMed]

57. Tanaka, M.; Török, N.; Vécel, L. Novel Pharmaceutical Approaches in Dementia. In *NeuroPsyhoparmacotherapy*; Riederer, P., Laux, G., Nagatsu, T., Le, W., Riederer, C., Eds.; Springer International Publishing: Cham, Switzerland, 2020; pp. 1–18. [CrossRef]

58. Weller, J.; Budson, A. Current understanding of Alzheimer’s disease diagnosis and treatment. *Fl1000Research* **2018**, *7*, 1161. [CrossRef] [PubMed]

59. Breijiyeh, Z.; Karaman, R. Comprehensive Review on Alzheimer’s Disease: Causes and Treatment. *Molecules* **2020**, *25*, 5789. [CrossRef] [PubMed]

60. Chu, L.W. Alzheimer’s disease: Early diagnosis and treatment. *Hong Kong Med. J.* **2012**, *18*, 228–237. [PubMed]

61. Mendiola-Precosa, J.; Berumen, L.C.; Padilla, K.; Garcia-Alcocer, G. Therapies for Prevention and Treatment of Alzheimer’s Disease. *BioMed. Res. Int.* **2016**, *2016*, S289276. [CrossRef] [PubMed]

62. Tanaka, M.; Bohár, Z.; Vécel, L. Are kynurenines accomplices or principal villains in dementia? Maintenance of kynurenine metabolism. *Molecules* **2020**, *25*, 564. [CrossRef]

63. Sharma, K. Cholinesterase inhibitors as Alzheimer’s therapeutics (Review). *Mol. Med. Rep.* **2019**, *20*, 1479–1487. [CrossRef]

64. Roy, J.; Tsui, K.C.; Ng, J.; Fung, M.-L.; Lim, L.W. Regulation of Melatonin and Neurotransmission in Alzheimer’s Disease. *Int. J. Mol. Sci.* **2021**, *22*, 6841. [CrossRef]

65. Moss, D.E. Improving anti-neurodegenerative benefits of acetylcholinesterase inhibitors in Alzheimer’s disease: Are irreversible inhibitors the future? *Int. J. Mol. Sci.* **2021**, *22*, 3438. [CrossRef]

66. Liu, J.; Chang, L.; Song, Y.; Li, H.; Wu, Y. The Role of NMDA Receptors in Alzheimer’s Disease. *Front. Neurosci.* **2019**, *13*, 43. [CrossRef]

67. Kornhuber, J.; Weller, M.; Schoppmeyer, K.; Riederer, P. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. *J. Neural Transm. Suppl.* **1994**, *43*, 91–104. [PubMed]

68. Kornhuber, J.; Bormann, J.; Hübner, M.; Rusche, K.; Riederer, P. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: A human postmortem brain study. *Eur. J. Pharmacol. Mol. Pharmacol.* **1991**, *210*, 297–300. [CrossRef]

69. Kornhuber, J.; Bormann, J.; Retz, W.; Hübner, M.; Riederer, P. Memantine displaces [3H] MK-801 at therapeutic concentrations in postmortem human frontal cortex. *Eur. J. Pharmacol.* **1989**, *166*, 589–590. [CrossRef]

70. Rogers, M.B. Anti-Agitation Drug Comes Up Short in Phase 3. 2019. Available online: https://www.alzforum.org/news-research-news/anti-agitation-drug-comes-short-phase-3 (accessed on 28 August 2021).

71. BI 425809. 2020. Available online: https://www.alzforum.org/therapeutics/bi-425809 (accessed on 28 August 2021).

72. Sacco, R.L.; DeRosa, J.T.; Haley, E.C., Jr.; Levin, B.; Ordronneau, P.; Phillips, S.J.; Rundek, T.; Snipes, R.G.; Thompson, J.L.; Glycine Antagonist in Neuroprotection Americas Investigators. Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: A randomized controlled trial. *JAMA* **2001**, *285*, 1719–1728. [CrossRef]

73. AXS-05. 2020. Available online: https://www.alzforum.org/therapeutics/axs-05 (accessed on 28 August 2021).

74. Uddin, M.; Kabir, M.; Rahman, M.; Behl, T.; Jeandet, P.; Ashraf, G.M.; Najda, A.; Bin-Jumah, M.N.; El-Seedi, H.R.; Abdel-Daim, M.M. Revisiting the amyloid cascade hypothesis: From anti-β therapeutics to auspicious new ways for Alzheimer’s disease. *Int. J. Mol. Sci.* **2020**, *21*, 5858. [CrossRef]

75. Solanezumab. 2021. Available online: https://www.alzforum.org/therapeutics/solanezumab (accessed on 29 August 2021).

76. Aduhelm. 2021. Available online: https://www.alzforum.org/therapeutics/aduhelm (accessed on 29 August 2021).

77. Therapeutics. 2021. Available online: https://www.alzforum.org/therapeutics/gv-971%3e (accessed on 29 August 2021).

78. Solanezumab. 2021. Available online: https://www.alzforum.org/therapeutics/solanezumab (accessed on 29 August 2021).

79. Farina, N.; Llewellyn, D.; Isaac, M.; Cummings, J. Repurposed agents in the Alzheimer’s disease drug development pipeline. *Alzheimers Res. Ther.* **2020**, *12*, 98. [CrossRef] [PubMed]

80. Uddin, M.; Kabir, M.; Rahman, M.; Behl, T.; Jeandet, P.; Ashraf, G.M.; Najda, A.; Bin-Jumah, M.N.; El-Seedi, H.R.; Abdel-Daim, M.M. Revisiting the amyloid cascade hypothesis: From anti-β therapeutics to auspicious new ways for Alzheimer’s disease. *Int. J. Mol. Sci.* **2020**, *21*, 5858. [CrossRef]

81. Masitinib. 2021. Available online: https://www.alzforum.org/therapeutics/masitinib (accessed on 29 August 2021).

82. Hoyer, D.; Allen, A.; Jacobson, L.H. Hypnotics with novel modes of action. *Br. J. Clin. Pharmacol.* **2020**, *86*, 244–249. [CrossRef]

83. Forbes, D.; Forbes, S.C.; Blake, C.M.; Thiessen, E.J.; Forbes, S. Exercise programs for people with dementia. *Cochrane Database Syst. Rev.* **2015**, CD006489. [CrossRef]

84. Pfaff, A.L.; Bubb, V.J.; Quinn, J.P.; Koks, S. An increased burden of highly active retrotransposition competent L1s is associated with Parkinson’s Disease risk and progression in the PPMI Cohort. *Int. J. Mol. Sci.* **2020**, *21*, 6562. [CrossRef]

85. Baeken, M.W.; Moosmann, B.; Hajieva, P. Retrotransposon activation by distressed mitochondria in neurons. *Biochem. Biophys. Res. Commun.* **2020**, *525*, 570–575. [CrossRef]

86. Taguchi, Y.; Wang, H. Exploring MicroRNA Biomarkers for Parkinson’s Disease from mRNA Expression Profiles. *Cells* **2018**, *7*, 245. [CrossRef]

87. Brito, L.M.; Ribeiro-dos-Santos, A.; Vidal, A.F.; de Araújo, G.S. Differential expression and mirna–gene interactions in early and late mild cognitive impairment. *Biochemistry* **2020**, *9*, 251. [CrossRef]

88. Catanesi, M.; d’Angelo, M.; Tupone, M.G.; Benedetti, E.; Giordano, A.; Castelli, V.; Cimini, A. MicroRNAs dysregulation and mitochondrial dysfunction in neurodegenerative diseases. *Int. J. Mol. Sci.* **2020**, *21*, 5986. [CrossRef]
89. Martinez, B.; Peplow, P.V. MicroRNAs in blood and cerebrospinal fluid as diagnostic biomarkers of multiple sclerosis and to monitor disease progression. *Neural Regen. Res.* 2020, 15, 606–619. [CrossRef][PubMed]

90. Lanfranco, M.F.; Ng, C.A.; Rebeck, G.W. ApoE lipidation as a therapeutic target in Alzheimer’s disease. *Int. J. Mol. Sci.* 2020, 21, 6336. [CrossRef][PubMed]

91. Safieh, M.; Korczyn, A.D.; Michaelson, D.M. ApoE4: An emerging therapeutic target for Alzheimer’s disease. *BMC Med.* 2019, 17, 64. [CrossRef][PubMed]

92. O’Day, D.H. Calmodulin binding proteins and Alzheimer’s disease: Biomarkers, regulatory enzymes and receptors that are regulated by calmodulin. *Int. J. Mol. Sci.* 2020, 21, 7344. [CrossRef][PubMed]

93. Erabi, H.; Okada, G.; Shibasaki, C.; Setoyama, D.; Kang, D.; Takamura, M.; Yoshino, A.; Fuchikami, M.; Kurata, A.; Kato, T.A.; et al. Kynurenic acid is a potential overlapped biomarker between diagnosis and treatment response for depression from metabolome analysis. *Sci. Rep.* 2020, 10, 16822. [CrossRef]

94. Jovanovic, F.; Candido, K.D.; Knezovic, N.N. The role of the kynurenine signaling pathway in different chronic pain conditions and potential use of therapeutic agents. *Int. J. Mol. Sci.* 2020, 21, 6045. [CrossRef][PubMed]

95. Hunt, B.C.; Cordeiro, T.M.E.; Robert, S.; de Dios, C.; Leal, V.A.C.; Soares, J.C.; Robert, D.; Antonio, T.; Sudhakar, S.M. Effect of immune Activation on the Kynurenine Pathway and Depression Symptoms—A Systematic Review and Meta-Analysis. *Neurosci. Biobehav. Rev.* 2020, 118, 514–523. [CrossRef]

96. Ulivieri, M.; Wieronska, J.M.; Lionetto, L.; Martinello, K.; Cieslik, P.; Chocyk, A.; Curto, M.; Di Menna, L.; Iacovelli, L.; Traficante, A. The trace kynurenine, cinnabarinic acid, displays potent antipsychotic-like activity in mice and its levels are reduced in the prefrontal cortex of individuals affected by schizophrenia. *Schizophr. Bull.* 2020, 46, 1471–1481. [CrossRef]

97. Tórkö, N.; Maszlak-Tórkö, R.; Molnár, K.; Szolnoki, Z.; Somogyvári, F.; Boda, K.; Tanaka, M.; Klivényi, P.; Vécsei, L. Single nucleotide polymorphisms of Indoleamine 2, 3-Dioxygenase 1 influenced the age onset of Parkinson’s disease. *Preprints 2020, 2020010172. [CrossRef]

98. Zhao, Q.F.; Tan, L.; Wang, H.F.; Jiang, T.; Tan, M.S.; Tan, L.; Xu, W.; Li, J.Q.; Wang, J.; Lai, T.J.; et al. The prevalence of neuropsychiatric symptoms in Alzheimer’s disease: Systematic review and meta-analysis. *J. Affect. Disord.* 2016, 190, 264–271. [CrossRef]

99. Muntsant, A.; Jiménez-Altayó, F.; Puertas-Umbert, L.; Jiménez-Xarrie, E.; Vila, E.; Giménez-Llort, L. Sex-Dependent End-of-Life Mental and Vascular Scenarios for Compensatory Mechanisms in Mice with Normal and AD-Neurodegenerative Aging. *Biomedicines* 2021, 9, 111. [CrossRef]

100. López-Gambero, A.J.; Sanjuan, C.; Serrano-Castro, P.J.; Suárez, J.; Rodriguez de Fonseca, F. The Biomedical Uses of Inositolos: A Nutraceutical Approach to Metabolic Dysfunction in Aging and Neurodegenerative Diseases. *Biomedicines* 2020, 8, 295. [CrossRef]

101. Hamani, C.; McAndrews, M.P.; Cohn, M.; Oh, M.; Zumsteg, D.; Shapiro, C.M.; Wennberg, R.A.; Lozano, A.M. Memory enhancement induced by hypothalamic/fornix deep brain stimulation. *Ann. Neurol.* 2008, 63, 119–123. [CrossRef]

102. Liu, A.; Jain, N.; Vyas, A.; Lim, L.W. Ventromedial prefrontal cortex stimulation enhances memory and hippocampal neurogenesis in the middle-aged rats. *elife* 2015, 4, e04803. [CrossRef]

103. Tan, S.Z.K.; Du, R.; Perucho, J.A.U.; Chopra, S.S.; Vardhanabhuti, V.; Lim, L.W. Dropout in Neural Networks Simulates the Paradoxical Effects of Deep Brain Stimulation on Memory. *Front. Aging Neurosci.* 2020, 12, 273. [CrossRef][PubMed]

104. Tan, S.Z.K.; Neoh, J.; Lawrence, A.J.; Wu, E.X.; Lim, L.W. Premotor Cortical Stimulation Improves Spatial Memory Through Distinct Patterns of Hippocampal Gene Expression in Aged Rats. *Neurotherapeutics* 2020, 17, 2054–2068. [CrossRef][PubMed]

105. Tan, S.Z.K.; Poon, C.H.; Chan, Y.S.; Lim, L.W. Premotor cortical stimulation disrupts fear memory consolidation through ventral hippocampal dopamine D2 receptors. *Br. J. Pharmacol.* 2021, 178, 3587–3601. [CrossRef][PubMed]

106. Hescham, S.; Jahanshahi, A.; Merialux, C.; Lim, L.W.; Blokland, A.; Temel, Y. Behavioral effects of deep brain stimulation of different areas of the Papez circuit on memory- and anxiety-related functions. *Behav. Brain Res.* 2015, 292, 353–360. [CrossRef][PubMed]

107. Hescham, S.; Lim, L.W.; Jahanshahi, A.; Blokland, A.; Temel, Y. Deep brain stimulation in dementia-related disorders. *Neurosci. Biobehav. Rev.* 2013, 37, 2666–2675. [CrossRef]

108. Hescham, S.; Lim, L.W.; Jahanshahi, A.; Steinbusch, H.W.; Pickræerts, J.; Blokland, A.; Temel, Y. Deep brain stimulation of the fornix area enhances memory functions in experimental dementia: The role of stimulation parameters. *Brain Stimul.* 2013, 6, 72–77. [CrossRef][PubMed]

109. Lim, L.W.; Janssen, M.L.; Kocabicak, E.; Temel, Y. The antidepressant effects of ventromedial prefrontal cortex stimulation is associated with neural activation in the medial part of the subthalamic nucleus. *Behav. Brain Res.* 2015, 279, 17–21. [CrossRef][PubMed]

110. Lim, L.W.; Pickræerts, J.; Huguet, G.; Kadar, E.; Hartung, H.; Sharp, T.; Temel, Y. Electrical stimulation alleviates depressive-like behaviors of rats: Investigation of brain targets and potential mechanisms. *Transl. Psychiatry* 2015, 5, e353. [CrossRef][PubMed]

111. Small, G.; Bullock, R. Defining optimal treatment with cholinesterase inhibitors in Alzheimer’s disease. *Alzheimers Dement.* 2011, 7, 177–184. [CrossRef]

112. Blanco-Silvente, L.; Castells, X.; Saez, M.; Barcelo, M.A.; Garre-Olmo, J.; Vilalta- Franj, J.; Capellà, D. Discontinuation, Efficacy, and Safety of Cholinesterase Inhibitors for Alzheimer’s Disease: A Meta-Analysis and Meta-Regression of 43 Randomized Clinical Trials Enrolling 16 106 Patients. *Int. J. Neuropsychopharmacol.* 2017, 20, 519–528. [CrossRef][PubMed]
140. Lu, M.H.; Ji, W.L.; Chen, H.; Sun, Y.Y.; Zhao, X.Y.; Wang, F.; Shi, Y.; Hu, Y.N.; Liu, B.X.; Wu, J.W.; et al. Intranasal Transplantation of Human Neural Stem Cells Ameliorates Alzheimer’s Disease-Like Pathology in a Mouse Model. *Front. Aging Neurosci.* 2021, 13, 650103. [CrossRef]

141. Li, X.; Zhu, H.; Sun, X.; Zuo, F.; Lei, J.; Wang, Z.; Bao, X.; Wang, R. Human Neural Stem Cell Transplantation Rescues Cognitive Deficits in APP/PS1 Model of Alzheimer’s Disease by Enhancing Neuronal Connectivity and Metabolic Activity. *Front. Aging Neurosci.* 2016, 8, 282. [CrossRef] [PubMed]

142. Lee, I.-S.; Jung, K.; Kim, J.-S.; Lee, H.; Kim, M.; Yun, S.; Hwang, K.; Shin, J.E.; Park, K.I. Human neural stem cells alleviate Alzheimer-like pathology in a mouse model. *Mol. Neurodegener.* 2015, 10, 38. [CrossRef]

143. Ager, R.R.; Davis, J.L.; Agazaryan, A.; Benavente, F.; Poon, W.W.; La Ferla, F.M.; Blurton-Jones, M. Human neural stem cells improve cognition and promote synaptic growth in two complementary transgenic models of Alzheimer’s disease and neuronal loss. *Hippocampus* 2015, 25, 813–826. [CrossRef]

144. Zhu, Q.; Zhang, N.; Hu, N.; Jiang, R.; Lu, H.; Xuan, A.; Long, D.; Chen, Y. Neural stem cell transplantation improves learning and memory by protecting cholinergic neurons and restoring synaptic impairment in an amyloid precursor protein/presenilin 1 transgenic mouse model of Alzheimer’s disease. *Mol. Med. Rep.* 2020, 21, 1172–1180. [CrossRef]

145. Clinical Trial with Human ES Cells for Congenital Urea Cycle Disorder—World’s First Transplantation of Human ES Cell-Derived Hepatocytes into Humans. 2020. Available online: https://www.amed.go.jp/en/news/release_20200521.html (accessed on 29 August 2021).

146. Mendonça, M.V.; Larroca, T.F.; de Freitas Souza, B.S.; Villarreal, C.F.; Silva, L.F.; Matos, A.C.; Novaes, M.A.; Bahia, C.M.; de Oliveira Melo Martínez, A.C.; Kaneto, C.M.; et al. Safety and neurological assessments after autologous transplantation of bone marrow mesenchymal stem cells in subjects with chronic spinal cord injury. *Stem Cell Res. Ther.* 2014, 5, 126. [CrossRef]

147. Alzheimer’s Association. 2015 Alzheimer’s Disease Facts and Figures. *Alzheimers Dement.* 2015, August, 307, 171–190. [CrossRef]

148. Rodrigues, F.B.; Wild, E.J. Huntington’s Disease Clinical Trials Corner: August 2018. *J. Huntington. Dis.* 2018, 7, 279–286. [CrossRef]

149. D’Souza, M.L. Regenerative medicine: Could Parkinson’s be the first neurodegenerative disease to be cured? *Future Sci. OA* 2019, 5, Fso418. [CrossRef]

150. Colagiuri, B.; Schenk, L.A.; Kessler, M.D.; Dorsey, S.G.; Colloca, L. Characteristics, applications and prospects of mesenchymal stem cells in cell therapy. *Med. Clin.* 2017, 148, 408–414. [CrossRef] [PubMed]

151. Martello, G.; Smith, A. The nature of embryonic stem cells. *Stem Cell Res. Ther.* 2018, 9, 1–11. [CrossRef] [PubMed]

152. Colagiuri, B.; Schenk, L.A.; Kessler, M.D.; Dorsey, S.G.; Colloca, L. The placebo effect: From concepts to genes. *Neuroscience* 2015, 307, 171–190. [CrossRef] [PubMed]

153. Poulos, J. The limited application of stem cells in medicine: A review. *Cell Transplant.* 2018, 27, 282. [CrossRef] [PubMed]

154. Bluerton-Jones, M.; Kitzazawa, M.; Martinez-Coria, H.; Castello, N.A.; Müller, F.J.; Loring, J.F.; Yamasaki, T.R.; Poon, W.W.; Green, K.N.; LaFerla, F.M. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. *Proc. Natl. Acad. Sci. USA* 2009, 106, 13594–13599. [CrossRef] [PubMed]

155. Martello, G.; Smith, A. The nature of embryonic stem cells. *Annu. Rev. Cell Dev. Biol.* 2014, 30, 647–675. [CrossRef]

156. Baldwin, K.T.; Eroglu, C. Molecular mechanisms of astrocyte-induced synaptogenesis. *Curr. Opin. Neurobiol.* 2017, 45, 113–120. [CrossRef] [PubMed]

157. Blurton-Jones, M.; Kitzazawa, M.; Martinez-Coria, H.; Castello, N.A.; Müller, F.J.; Loring, J.F.; Yamasaki, T.R.; Poon, W.W.; Green, K.N.; LaFerla, F.M. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. *Proc. Natl. Acad. Sci. USA* 2009, 106, 13594–13599. [CrossRef] [PubMed]

158. Bartlett, J.; Kawamura, K.; Nakashima, H. Histological signs of immune reactions against allogeneic solid fetal neural grafts in the mouse cerebellum depend on the MHC locus. *Exp. Brain Res.* 1988, 73, 15–22. [CrossRef]

159. Juengst, E.; Fossel, M. The Ethics of Embryonic Stem Cells—Now and Forever, Cells Without End. *JAMA* 2000, 284, 3180–3184. [CrossRef]

160. Jin, X.; Lin, T.; Xu, Y. Stem Cell Therapy and Immunological Rejection in Animal Models. *Annu. Rev. Cell Dev. Biol.* 2014, 30, 73–92. [CrossRef] [PubMed]

161. Baldwin, K.T.; Eroglu, C. Molecular mechanisms of astrocyte-induced synaptogenesis. *Curr. Opin. Neurobiol.* 2017, 45, 113–120. [CrossRef] [PubMed]

162. Blurton-Jones, M.; Kitzazawa, M.; Martinez-Coria, H.; Castello, N.A.; Müller, F.J.; Loring, J.F.; Yamasaki, T.R.; Poon, W.W.; Green, K.N.; LaFerla, F.M. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. *Proc. Natl. Acad. Sci. USA* 2009, 106, 13594–13599. [CrossRef] [PubMed]

163. Date, I.; Kawamura, K.; Nakashima, H. Histological signs of immune reactions against allogeneic solid fetal neural grafts in the mouse cerebellum depend on the MHC locus. *Exp. Brain Res.* 1988, 73, 15–22. [CrossRef]
166. Aguila, J.C.; Hedlund, E.; Sanchez-Pernaute, R. Cellular Programming and Reprogramming: Sculpting Cell Fate for the Production of Dopamine Neurons for Cell Therapy. *Stem Cells Int.* 2012, 2012, 412040. [CrossRef]